Shares of Akorn, Inc. (NASDAQ:AKRX) traded down 5.4% during trading on Friday . The stock traded as low as $4.03 and last traded at $4.04. 1,223,564 shares changed hands during trading, a decline of 55% from the average session volume of 2,697,858 shares. The stock had previously closed at $4.27.
Several analysts recently commented on the stock. Piper Jaffray Companies set a $8.00 target price on shares of Akorn and gave the company a “buy” rating in a research note on Friday, March 1st. Zacks Investment Research raised shares of Akorn from a “sell” rating to a “hold” rating in a research note on Wednesday, May 1st. BidaskClub raised shares of Akorn from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, February 20th. Royal Bank of Canada set a $4.00 target price on shares of Akorn and gave the company a “hold” rating in a research note on Friday, March 1st. Finally, SunTrust Banks assumed coverage on shares of Akorn in a research note on Tuesday, March 19th. They set a “hold” rating and a $4.00 target price for the company. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and three have given a buy rating to the company. Akorn presently has a consensus rating of “Hold” and a consensus price target of $8.33.
The company has a debt-to-equity ratio of 2.31, a quick ratio of 2.30 and a current ratio of 3.26. The stock has a market cap of $552.48 million, a P/E ratio of -11.22 and a beta of 2.60.
In other news, Director Steven J. Meyer purchased 15,000 shares of Akorn stock in a transaction that occurred on Monday, May 20th. The stock was acquired at an average price of $4.10 per share, for a total transaction of $61,500.00. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Terry Allison Rappuhn purchased 10,000 shares of Akorn stock in a transaction that occurred on Monday, May 13th. The stock was purchased at an average price of $4.03 per share, with a total value of $40,300.00. The disclosure for this purchase can be found here. 3.90% of the stock is currently owned by corporate insiders.
Several large investors have recently modified their holdings of AKRX. MML Investors Services LLC purchased a new stake in shares of Akorn in the 4th quarter valued at approximately $34,000. Oregon Public Employees Retirement Fund increased its stake in Akorn by 228.2% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 121,338 shares of the company’s stock valued at $36,000 after buying an additional 84,363 shares during the period. Jane Street Group LLC acquired a new position in Akorn in the 1st quarter valued at approximately $44,000. Piedmont Investment Advisors Inc. acquired a new position in Akorn in the 4th quarter valued at approximately $76,000. Finally, Virtu Financial LLC acquired a new position in Akorn in the 4th quarter valued at approximately $87,000. Institutional investors and hedge funds own 68.83% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Akorn (AKRX) Stock Price Down 5.4%” was published by Markets Daily and is the property of of Markets Daily. If you are accessing this article on another website, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this article can be accessed at https://www.themarketsdaily.com/2019/05/24/akorn-akrx-stock-price-down-5-4.html.
Akorn Company Profile (NASDAQ:AKRX)
Akorn, Inc, a specialty generic pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health.
Recommended Story: Understanding Market Liquidity
Receive News & Ratings for Akorn Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akorn and related companies with MarketBeat.com's FREE daily email newsletter.